See Shionogi-Sponsored Publications

Publications

Here, you can review available Shionogi-sponsored publications. If you would like an electronic copy of one of the journal publications on this page, please contact
Shionogi Medical Information for further assistance.

Information about investigational compounds or investigational uses of products does not imply FDA approval of these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the investigational compounds or investigational uses of products will receive FDA approval. Shionogi does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling.

  • All
  • Cefiderocol
  • Ensitrelvir
  • Zatolmilast
  • All
  • In vitro
  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4
  • Real-world evidence
  • Surveillance
  • Review
  • Pharmacokinetics/Pharmaco-dynamics
  • Compatibility
  • All
  • Gram-negative infection
  • COVID-19
  • Fragile X syndrome
 
Cefiderocol
Real-world evidence
Gram-negative infection

Cefiderocol treatment for patients infected by Stenotrophomonas maltophilia, Burkholderia cepacia complex and Achromobacter spp.: subgroup analysis from the PERSEUS study

Published:
2025
Authors:
Torre-Cisneros J, Ferrer R, De La Fuente Martos C, et al.
View Publication
 
Cefiderocol
Real-world evidence
Gram-negative infection

Effectiveness and safety of cefiderocol treatment in patients with Gram-negative bacterial infections in Spain in the early access programme: results of the PERSEUS study

Published:
2025
Authors:
Torre-Cisneros J, Almirante B, De La Fuente Martos C, et al.
View Publication
 
Ensitrelvir
Real-world evidence
Surveillance
COVID-19

Ensitrelvir for the treatment of COVID-19: Final analysis of a post-marketing surveillance from Japan

Published:
2025
Authors:
Hayashi N, Tsukimura E, Ogura E
View Publication
 
Ensitrelvir
Phase 3
COVID-19

Ensitrelvir for the treatment of nonhospitalized adults with COVID-19: Results from the SCORPIO-HR, phase 3, randomized, double-blind, placebo-controlled trial

Published:
2025
Authors:
Luetkemeyer AF, Chew KW, Lacey S, et al.
View Publication
 
Ensitrelvir
Phase 3
COVID-19

Ensitrelvir treatment–emergent amino acid substitutions in SARS-CoV-2 3CLpro detected in the SCORPIO-SR phase 3 trial

Published:
2025
Authors:
Uehara T, Yotsuyanagi H, Ohmagari N, et al.
View Publication